James R. Whittle - Concepedia

Author

James R. Whittle

Also Known As

J R Whittle, J Whittle, J. Whittle, J.R. Whittle, James R Whittle, James R. Whittle, James Richard Whittle, James Whittle, Jim R Whittle

104

Publications

Citations

H-Index

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne Walter and Eliza Hall Institute of Medical Research The Royal Melbourne Hospital Monash University

About

James R. Whittle is an author at Peter MacCallum Cancer Centre specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	590
2	Engineering	4	4	325
3	Health Sciences	1	1	16
4	Biochemistry	1	1	12
5	Biomedical Engineering	1	1	112

James R. Whittle

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation Zuoren Yu, Chenguang Wang, Min Wang, The Journal of Cell Biology	2008	364
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer Delphine Mérino, James R. Whittle, François Vaillant, Science Translational Medicine Breast OncologyBh3 MimeticsMedicineHer2-amplified Breast CancerCrispr-associated 9	2017	190
Modeling Breast Cancer Using CRISPR-Cas9–Mediated Engineering of Human Breast Organoids Johanna F. Dekkers, James R. Whittle, François Vaillant, JNCI Journal of the National Cancer Institute Breast OncologyEngineeringFunctional HeterogeneityTumor BiologyTumor Heterogeneity	2019	177
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer Sheau Wen Lok, James R. Whittle, François Vaillant, Cancer Discovery	2019	143
First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma James R. Whittle, Jason D. Lickliter, Hui Gan, Journal of Clinical Neuroscience NanomedicineNeuro-oncologyDrug TargetingEngineeringTherapeutic Nanomaterials	2015	112
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer James R. Whittle, François Vaillant, Elliot Surgenor, Clinical Cancer Research	2020	96
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer Shikhar Sharma, Chi‐Yeh Chung, Sean Uryu, Cell chemical biology	2023	59
Targeting triple-negative breast cancers with the Smac-mimetic birinapant Najoua Lalaoui, Delphine Mérino, Göknur Giner, Cell Death and Differentiation	2020	48
Spatial architecture of high-grade glioma reveals tumor heterogeneity within distinct domains Joel J D Moffet, Oluwaseun E. Fatunla, Lutz Freytag, Neuro-Oncology Advances	2023	47
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma Ryan J. Duchatel, Evangeline R. Jackson, Sarah Parackal, Journal of Clinical Investigation	2024	30

Page 1